85 Results for "

anticancer antibodies

" in MedChemExpress (MCE) Product Catalog:
Products (85)

85 Results for "anticancer antibodies" in MCE Product Catalog:

12
12 Publications Verification
Cat. No.: HY-132254
CAS No.: 1491917-83-9
Purity:  99.13%
Synonyms: IMMU-132
Research Areas:  

Cancer

Sacituzumab govitecan (IMMU-132) is an antibody-drug conjugate (ADC) targeting Trop-2 for delivery of SN-38. The antibody portion is Sacituzumab (HY-P99045), and the drug-linker conjugate for ADC is CL2A-SN-38 (HY-128946). Sacituzumab govitecan shows anticancer activity .
loading...
    loading...
12
12 Publications Verification
Cat. No.: HY-132254A
CAS No.: 1491917-83-9
Purity:  96.61%
Synonyms: IMMU-132 (solution)
Research Areas:  

Cancer

Sacituzumab govitecan (IMMU-132) is an antibody-drug conjugate (ADC) targeting Trop-2 for delivery of SN-38. The antibody portion is Sacituzumab (HY-P99045), and the drug-linker conjugate for ADC is CL2A-SN-38 (HY-128946). Sacituzumab govitecan shows anticancer activity .
loading...
    loading...
4
4 Cited Publications
Cat. No.: HY-P99156
CAS No.: 1673516-98-7
Synonyms: BMS-986016

Target:  

LAG-3

Research Areas:  

Cancer

Relatlimab (BMS-986016) is a human monoclonal antibody anti-LAG-3 antibody generated by immunization of transgenic mice bearing human immunoglobulin miniloci with recombinant LAG-3 protein. Relatlimab blocks LAG-3/MHC II interaction with an IC50 value of 0.67 nM and LAG-3/FGL1 interaction with an IC50 value of 0.019 nM. Relatlimab can be used in research of cancer .
loading...
    loading...
3
3 Cited Publications
Cat. No.: HY-P9977
CAS No.: 2171511-58-1
Synonyms: JNJ-61186372

Target:  

EGFR

Research Areas:  

Cancer

Amivantamab (JNJ-61186372) is a human EGFR-MET bispecific antibody with immune anticancer activity. Amivantamab inhibits ligand binding, promotes endocytosis and degradation of receptor-antibody complexes, and induces Fc-dependent cytokinesis in macrophages and antibody-dependent cytotoxicity in natural killer cells .
loading...
    loading...
2
2 Cited Publications
Cat. No.: HY-P99100
CAS No.: 2556646-63-8
Synonyms: CTL-002

Research Areas:  

Cancer

Visugromab (CTL-002) is a GDF-15 neutralizing IgG4 mAb. Visugromab has synergistic anticancer activity with the anti-PD1 antibody Nivolumab (HY-P9903) and can effectively act on PD-1/PD-L1 relapsed/refractory metastatic solid tumors. Recommend Isotype Controls: Human IgG4 (S228P) kappa, Isotype Control (HY-P99003) .
loading...
    loading...
2
2 Cited Publications
Cat. No.: HY-141604
CAS No.: 1182215-65-1
Purity:  99.90%
Synonyms: CDX-011; CR011-vcMMAE
Glembatumumab vedotin (CDX-011) is an ADC comprising a fully human IgG2 monoclonal antibody (CR011) directed against glycoprotein NMB (GPNMB) and conjugated to the potent tubulinbinding cytotoxic agent MMAE via a protease-sensitive vc linker. Glembatumumab vedotin has potent anticancer effects .
loading...
    loading...
1
1 Cited Publications
Cat. No.: HY-P99675
CAS No.: 2428381-53-5
Synonyms: AK112

Target:  

PD-1/PD-L1 VEGFR

Research Areas:  

Cancer

Ivonescimab (AK112) is a PD-1/VEGF bispecific antibody. Ivonescimab competitively inhibiting PD-1/PD-L1 interaction, reversing the immunosuppression mediated by it, and blocks the binding of VEGF-A to VEGFR2, inhibiting tumour angiogenesis in the tumour microenvironment. Ivonescimab also has significantly anticancer activity against EGFR-mutated locally advanced or metastatic non-squamous non-small cell lung cancer (NSCL) .
loading...
    loading...
1
1 Cited Publications
Cat. No.: HY-P99854
CAS No.: 2185868-98-6
Synonyms: RC48-0

Target:  

EGFR ADC Antibodies

Research Areas:  

Cancer

Disitamab (RC48-0) is a humanized monoclonal antibody targeting HER2. Disitamab can be used in the synthesis of antibody-drug conjugates (ADCs), Disitamab vedotin (HY-P9985) .
loading...
    loading...
1
1 Cited Publications
Cat. No.: HY-145626
CAS No.: 2460399-44-2
Purity:  99.73%
Synonyms: BA302

Target:  

ADC Antibodies ROR

Research Areas:  

Cancer

Ozuriftamab is a human IgG1 kappa antibody of ROR2. Ozuriftamab can be used to synthesize ADC such as Ozuriftamab vedotin (HY-145627). Recommend Isotype Controls: Human IgG1 kappa, Isotype Control (HY-P99001) .
loading...
    loading...
1
1 Cited Publications
Cat. No.: HY-P99284
CAS No.: 1005389-60-5
Synonyms: MK-0646; h7C10

Target:  

IGF-1R Apoptosis

Research Areas:  

Cancer

Dalotuzumab (MK-0646) is a recombinant humanized monoclonal antibody (IgG1 type) targeting IGF-1R. Dalotuzumab acts by inhibiting IGF-1- and IGF-2-mediated tumor cell proliferation, IGF-1R autophosphorylation, and Akt phosphorylation. Dalotuzumab also induces apoptosis and cycle arrest. Dalotuzumab in combination with other anticancer agents such as statins can enhance the antitumor activity of Dalotuzumab in vitro and in vivo .
loading...
    loading...
Cat. No.: HY-128915
CAS No.: 1116745-06-2
Purity:  99.69%
Research Areas:  

Cancer

Duocarmycin DM free base, a DNA minor-groove alkylator, is an antibody agent conjugates (ADCs) toxin. Duocarmycin DM free base is based on its characteristic curved indole structure and a spirocyclopropylcyclohexadienone electrophile to act anticancer activity .
loading...
    loading...
Cat. No.: HY-P99329
CAS No.: 1436390-63-4
Synonyms: Anti-Human CD33 Recombinant Antibody

Research Areas:  

Cancer

Vadastuximab (Anti-Human CD33 Recombinant Antibody) is a humanized monoclonal antibody targeting CD33. Vadastuximab can be used to synthesize an ADC compound, Vadastuximab talirine .
loading...
    loading...
Cat. No.: HY-177439
Research Areas:  

Cancer

HLX43 is an antibody-drug conjugate (ADC) targeting PD-L1. HLX43 consists of a human monoclonal antibody anti-PD-L1 antibody Opucolimab (HY-P99785) with the drug-linker conjugate being DL-01 (HY-155870A). HLX43 exerts superior anticancer efficacy with safety profile in vivo. HLX43 can be used for non-small cell lung cancer (NSCLC), head and neck squamous cell carcinoma (HNSCC), esophageal squamous cell carcinoma (ESCC), melanoma (MEL), ovarian cancer (Ovc) research .
loading...
    loading...
Cat. No.: HY-P99330
CAS No.: 1448221-05-3
Synonyms: Anti-Human VEGFA Recombinant Antibody; RO5520985

Target:  

VEGFR Tie

Research Areas:  

Cancer

Vanucizumab is a first-in-class, bispecific IgG1-like monoclonal antibody that simultaneously blocks VEGF-A and angiopoietin-2 (Ang-2) from interacting with their receptors. Vanucizumab has antiangiogenic and anticancer effects .
loading...
    loading...
Cat. No.: HY-P99455
CAS No.: 2437210-79-0
Synonyms: EMB-01

Target:  

EGFR c-Met/HGFR

Research Areas:  

Cancer

Bafisontamab (EMB-01) is a bispecific antibody targeting EGFR and cMET with antitumor activity .
loading...
    loading...
Cat. No.: HY-117371
CAS No.: 157207-90-4
Purity:  99.90%
Synonyms: (-)-Hemiasterlin; Milnamide B
Hemiasterlin ((-)-Hemiasterlin) is an antimitotic marine natural product with potent anticancer effects. Hemiasterlin can be used as a cytotoxic payload (ADC Cytotoxin) in antibody-drug conjugates (ADCs) .
loading...
    loading...
Cat. No.: HY-P99517
CAS No.: 2411871-58-2
Synonyms: JNJ-63898081; JNJ-081

Target:  

CD3 PSMA

Research Areas:  

Cancer

Voxalatamab (JNJ-63898081) is a bispecific IgG4 antibody targeting PSMA and CD3. Voxalatamab attacks PSMA-expressing tumor cells by activating T cells. Voxalatamab has anticancer activity and is being studied for the treatment of solid tumors such as prostate cancer .
loading...
    loading...
Cat. No.: HY-P99153
CAS No.: 896723-44-7
Synonyms: MORAb-003

Target:  

Antibiotic

Research Areas:  

Cancer

Farletuzumab (MORAb-003) is a potent folate receptor-alpha (FRα) inhibitor. Farletuzumab is a humanized monoclonal antibody with high affinity for FRα. Farletuzumab possesses growth-inhibitory functions on cells overexpressing FRα. Farletuzumab can be used in research of cancer .
loading...
    loading...
Cat. No.: HY-147340
CAS No.: 2356230-22-1
Synonyms: Tirumotecan
Research Areas:  

Cancer

TL033 is a drug-Linker conjugates for ADC. TL033 contains a linker and bioactive small molecule toxins. TL033 can conjugate with Sacituzumab antibody (anti Trop-2) for synthesizing BT001021. BT001021 has anti-cancer activities against various cancers, such as breast cancer, non-small cell lung cancer (NSCLC), gastric cancer .
loading...
    loading...
Cat. No.: HY-147340A
CAS No.: 2746343-70-2
Synonyms: Tirumotecan TFA
Research Areas:  

Cancer

TL033 TFA is a drug-Linker conjugates for ADC. TL033 TFA contains a linker and bioactive small molecule toxins. TL033 TFA can conjugate with Sacituzumab antibody (anti Trop-2) for synthesizing BT001021. BT001021 has anti-cancer activities against various cancers, such as breast cancer, non-small cell lung cancer (NSCLC), gastric cancer .
loading...
    loading...